Stocks · News reference
Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients
The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full spectrum
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ImmunityBio shares are trading lower after the company reported a wider GAAP net loss for the second quarter reflecting a sharp increase in expenses.
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the
8-K filing — ImmunityBio, Inc. (IBRX)
Filed: 2026-08-04 AccNo: 0001326110-26-000077 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits